Hydroquinone face-cream routes: compare records before comparing strengths

Spot On’s product page describes a compounded cream with hydroquinone, kojic acid and niacinamide. The current offer cards add 6% hydroquinone and 6% kojic acid, while leaving niacinamide’s percentage, the complete base and supplied amount unestablished. Those facts should be confirmed in the actual prescription rather than inferred from an ingredient name. CoreAge description Offer

Its three-month option is $165 with $54.99 displayed monthly; one month is $70 with $69.99 displayed monthly. The same formula section separately says “From $42/mo,” without a corresponding checked plan. Our CoreAge review retains that discrepancy instead of promoting it as an available discount.

Obagi’s current Nu-Derm Clear page identifies prescription hydroquinone 4%, calls the product a cream and provides a listed inactive formulation. It directs readers to a healthcare provider or physician locator. The record does not establish a local stock position or a complete personal quote. Obagi Clear record

Clear Fx is a different arbutin-based cream with a $125 retail display on its separate page. That number is not the price of prescription Clear Rx. Similar branding, nearby comparison cards and a shared skin-discoloration category do not make the products interchangeable. The Obagi review explains which identity needs to appear in a professional’s quote. Clear Fx record

Dermatica’s melasma page lists hydroquinone 4% among possible prescription actives, alongside other ingredients and its SmartBase cream description. It does not establish that every person receives the whole menu or that a particular combination is equivalent to an approved medicine. A separate retinal serum also appears on the page and is not the hydroquinone prescription. Dermatica treatment page

The pricing page gives $29.95 per bottle and $59.90 every two months, with free shipping and approximately 56-day delivery wording. These units describe the service’s public offer. They do not resolve an individual formula or a clinical course. The Dermatica review separates those questions. Pricing

AAD notes that a professional may need close examination, specialized viewing or sometimes a biopsy to distinguish melasma from another condition. An article cannot determine that from a description of “dark spots.” Nor does a provider’s list of treated concerns establish a diagnosis for everyone who recognizes one of those phrases. AAD assessment context

The assessment guide treats uncertainty as something to discuss, not an obstacle to bypass. A comparison can show what each route says about professional involvement, but it cannot promise that an online service will be sufficient for every concern or that a named product will be prescribed.

FDA distinguishes compounded drugs from approved finished medicines. Its hydroquinone communication identifies Tri-Luma as the approved hydroquinone-containing product and describes a specific short-term facial melasma indication. A different cream does not inherit that status by sharing hydroquinone or requiring a prescription. FDA compounding FDA hydroquinone communication

That distinction also prevents an ingredient-count ranking. Spot On’s advertised 6% and Obagi’s 4% are product-description fields, not evidence that one has a preferable balance of benefit and risk. A personalized menu likewise does not prove that a mixture is more effective merely because more ingredients can be named.

A price comparison is incomplete if it does not identify whether a quote includes the clinical assessment, medication, dispensing, shipping and later review. The available records do not permit a verified all-in total across these routes. Obagi’s locator is not an appointment quote, and a monthly display should not conceal a larger order total.

Dermatica advertises check-ins and formula adaptations, with professional medical services distinguished in its terms from the platform. CoreAge similarly publishes a clinical-entity distinction. These are statements about intended responsibilities, not observed response times or completed coordination. The follow-up guide keeps clinical questions separate from billing or shipping support. Dermatica terms CoreAge service terms

FDA’s reports of hydroquinone-associated adverse effects include rash, swelling and ochronosis. Those reports do not provide a comparative incidence for these three routes. They do make a risk-free promise inappropriate, including one based solely on professional supervision or a limited commercial term. FDA safety record

AAD explains that melasma treatment is individualized and often includes sun-protection considerations. This publication does not turn that general context into a routine, duration or product selection. The useful result is a clearer set of records to request: the assessed concern, exact preparation, applicable quote and responsible professional. No comparison order supplies those missing answers. AAD treatment context